250
Participants
Start Date
August 31, 2016
Primary Completion Date
June 30, 2017
Study Completion Date
July 31, 2017
Bimekizumab
Subjects will be randomized to receive a combination of injections of Bimekizumab.
Placebo
Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Ps0010 711, Fremont
Ps0010 708, Los Angeles
Ps0010 706, Washington D.C.
Ps0010 704, West Des Moines
Ps0010 718, Rochester
Ps0010 738, Wilmington
Ps0010 736, Cleveland
Ps0010 712, Portland
Ps0010 733, Dallas
Ps0010 702, Houston
Ps0010 709, Houston
Ps0010 203, Surrey
Ps0010 204, Hamilton
Ps0010 201, North Bay
Ps0010 206, Peterborough
Ps0010 205, Waterloo
Ps0010 214, Québec
Ps0010 209, Edmonton
Ps0010 214, Québec
Ps0010 300, Ostrava Poruba
Ps0010 303, Pardubice
Ps0010 301, Prague
Ps0010 304, Prague
Ps0010 404, Kecskemét
Ps0010 400, Orosháza
Ps0010 405, Szekszárd
Ps0010 502, Nagoya
Ps0010 501, Shinaga Wa-ku
Ps0010 503, Tokyo
Ps0010 504, Tokyo
Ps0010 600, Bialystok
Ps0010 611, Bialystok
Ps0010 605, Gdansk
Ps0010 610, Gdynia
Ps0010 604, Kielce
Ps0010 608, Krakow
Ps0010 606, Lublin
Ps0010 603, Podlaski
Ps0010 607, Warsaw
Ps0010 601, Wroclaw
Ps0010 609, Wroclaw
Collaborators (1)
Parexel
INDUSTRY
UCB Biopharma S.P.R.L.
INDUSTRY